pre-IPO PHARMA

COMPANY OVERVIEW

Prolong Pharmaceuticals, LLC, is developing products to treat several diseases and their debilitating comorbidities associated with reduced quality of life, increased medical cost and significant mortality.


LOCATION

  • South Plainfield, NJ, USA

  • THERAPEUTIC AREAS

  • Hematology
  • Rare Diseases

  • WEBSITE

    https://www.prolongpharma.com/


    CAREER WEBSITE

    https://www.prolongpharma.com/the-career-center/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Dec 13, 2017

    Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting


    Nov 8, 2017

    Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease, at ASH Annual Meeting


    Apr 14, 2015

    Prolong Pharmaceuticals Presents Data on Unique "Un-Sickling" In Vitro Activity Observed in Sickle Cell Investigational Drug SANGUINATE


    Apr 8, 2015

    Prolong Pharmaceuticals' Flagship Product SANGUINATE™ Granted Orphan Drug Designation by the FDA


    Dec 18, 2013

    Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team


    For More Press Releases


    Google Analytics Alternative